Skip to main content
Sequana Medical N.V. logo

Sequana Medical N.V. — Investor Relations & Filings

Ticker · SEQUA ISIN · BE0974340722 LEI · 8755009AN12Y4PEOII07 BR Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2023-09-14 Interim / Quarterly Rep…
Country BE Belgium
Listing BR SEQUA

About Sequana Medical N.V.

https://www.sequanamedical.com/

Sequana Medical N.V. is a commercial-stage medical device company focused on developing treatments for drug-resistant fluid overload, a frequent complication in patients with liver disease, heart failure, and cancer. The company's primary product is the alfapump®, a fully implanted, wirelessly charged system that automatically and continuously removes ascites (fluid accumulation in the abdomen) into the bladder for natural elimination. It is the first U.S. FDA-approved active implantable medical device for treating recurrent or refractory ascites due to liver cirrhosis, designed to reduce or eliminate the need for therapeutic paracentesis. Sequana Medical is also advancing its DSR® (Direct Sodium Removal) therapy platform, a novel approach for managing fluid overload in heart failure patients.

Recent filings

Filing Released Lang Actions
Press Release_HY 2023 and business update_14 Sept 2023_ENG_vF.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the six-month period ending 30 June 2023 (H1 2023). It contains detailed financial statements, including a Condensed Consolidated Income Statement, Statement of Financial Position, and Statement of Cash Flows, along with a management discussion and analysis of the financial results. It is not merely an announcement or a short summary, but a substantive interim financial report. H1 2023
2023-09-14 English
Press Release_HY 2023 and business update_14 Sept 2023_NL_vF.pdf
Earnings Release Classification · 99% confidence The document explicitly states it reports 'resultaten H1 2023' (results for H1 2023) and provides a detailed 'Financieel overzicht – zes maanden eindigend op 30 juni 2023' (Financial overview - six months ended June 30, 2023), including a 'Verkorte geconsolideerde balans' and 'Verkort geconsolideerd kasstroomoverzicht'. This structure, covering a six-month period (half-year) with comprehensive financial statements, aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not an Annual Report (10-K) as it covers only six months, nor is it just an Earnings Release (ER) as it contains full condensed financial statements and management discussion, making it more comprehensive than a typical ER. H1 2023
2023-09-14 Dutch
230913- Sequana Medical Interim Cons FS June 2023 - ENG -noTC vFF.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a 'Condensed Consolidated Financial Statements' report for the six-month period ended 30 June 2023. It includes a statement from the Board of Directors, a statutory auditor's review report, and detailed financial statements (Income Statement, Statement of Financial Position, etc.). Since it covers a period shorter than a full fiscal year and contains substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2023
2023-09-14 English
230913 - Sequana Medical Interim Cons FS June 2023 - NL - vFF noTC.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a 'Verkorte Geconsolideerde Jaarrekening' (Condensed Consolidated Financial Statements) for the first semester of 2023. It includes a Board of Directors declaration, an auditor's review report, and detailed financial statements (balance sheet, income statement, cash flow, etc.). Since it covers a period shorter than a full fiscal year (six months) and contains substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2023
2023-09-14 Dutch
Press release_EASL presentation_21 June 2023_ENG_vF.pdf
Regulatory Filings Classification · 95% confidence The document is explicitly titled and formatted as a press release, containing the header "PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 21 June 2023, 07:00 am CEST". It announces specific clinical data updates (POSEIDON study results) and provides details about an upcoming conference call and webcast. This structure—announcing material, non-periodic information via a formal press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is focused on announcing new data and results rather than being a full quarterly/annual report (10-K or IR) or a transcript (CT), it fits best as an Earnings Release (ER) which often includes key operational and clinical updates, or RNS as a general regulatory announcement. Given the focus on presenting new data and scheduling a call to discuss it, ER is a strong candidate, but RNS is the most appropriate fallback for general regulated news that isn't a standard financial report or call transcript. However, since it details specific clinical trial results and includes management commentary, it functions similarly to an Earnings Release announcing operational/data milestones. Given the options, and the fact that it is a formal announcement of results and future discussion, I will classify it as an Earnings Release (ER) as it serves the function of reporting period-specific operational/data highlights, even if not strictly quarterly financials. If it were purely a notice about a report, RPA would apply, but this contains the substance of the news itself.
2023-06-21 English
Press release_EASL presentation_21 June 2023_NL_vF.pdf
Earnings Release Classification · 95% confidence The document is a press release from Sequana Medical NV, dated June 21, 2023, announcing 'bijkomende data' (additional data) regarding the safety, quality of life, and survival from their POSEIDON study for the alfapump. It details clinical results (efficacy endpoints, safety events, survival rates) and mentions that the data will be presented at the EASL Congress 2023. Crucially, it also announces a conference call/webcast for today to discuss these results. This structure—presenting key financial/clinical results immediately followed by an announcement of a call to discuss them—is characteristic of an Earnings Release (ER) or a major clinical/business update announcement. Since the content is focused on clinical trial results and not standard quarterly financial metrics (like revenue, net income, EPS), it aligns best with an announcement of significant operational/clinical progress. However, the document itself is a detailed press release announcing results and an upcoming call. It is not the full financial report (10-K/IR), a transcript (CT), or a presentation deck (IP). Given the focus on announcing key results and scheduling a call to discuss them, it fits the definition of an Earnings Release (ER) which often covers major operational milestones alongside financial highlights, or potentially a Regulatory Filing (RNS) if it were less specific. Since it is a structured announcement of study results and includes a call for discussion, ER is the closest fit for a major periodic update, even if clinical rather than purely financial. If it were purely an announcement of a report being available, RPA would apply, but here the results are detailed within the text. I will classify it as an Earnings Release (ER) as it functions as the primary communication of period-specific performance/milestones. H1 2023
2023-06-21 Dutch

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.